Nisa Investment Advisors LLC Buys 13,579 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Nisa Investment Advisors LLC boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 216.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,844 shares of the company’s stock after purchasing an additional 13,579 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Neurocrine Biosciences were worth $2,133,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Comerica Bank raised its stake in Neurocrine Biosciences by 3.3% in the third quarter. Comerica Bank now owns 3,933 shares of the company’s stock valued at $386,000 after buying an additional 125 shares during the last quarter. JGP Global Gestao de Recursos Ltda. raised its stake in Neurocrine Biosciences by 5.6% in the third quarter. JGP Global Gestao de Recursos Ltda. now owns 3,097 shares of the company’s stock valued at $279,000 after buying an additional 163 shares during the last quarter. Virginia Retirement Systems ET AL raised its stake in Neurocrine Biosciences by 1.2% in the third quarter. Virginia Retirement Systems ET AL now owns 17,000 shares of the company’s stock valued at $1,532,000 after buying an additional 200 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Neurocrine Biosciences by 70.5% in the second quarter. Tower Research Capital LLC TRC now owns 595 shares of the company’s stock valued at $51,000 after buying an additional 246 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in Neurocrine Biosciences by 2.8% in the third quarter. Janney Montgomery Scott LLC now owns 11,171 shares of the company’s stock valued at $1,007,000 after buying an additional 309 shares during the last quarter. 96.36% of the stock is currently owned by institutional investors.

In other news, insider Darin Lippoldt sold 10,000 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $110.01, for a total value of $1,100,100.00. Following the completion of the transaction, the insider now directly owns 26,728 shares in the company, valued at $2,940,347.28. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Matt Abernethy sold 1,645 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $116.33, for a total value of $191,362.85. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,465 shares of company stock valued at $4,237,168. Company insiders own 4.30% of the company’s stock.

A number of research firms have commented on NBIX. Oppenheimer increased their price target on Neurocrine Biosciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. TheStreet upgraded Neurocrine Biosciences from a “c+” rating to a “b” rating in a research note on Tuesday, November 19th. BidaskClub cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 13th. Credit Suisse Group cut Neurocrine Biosciences from an “outperform” rating to a “neutral” rating and set a $110.00 price target for the company. in a research note on Friday, December 13th. Finally, Zacks Investment Research upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating and set a $124.00 price target for the company in a research note on Wednesday, January 8th. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $116.92.

Shares of NASDAQ:NBIX opened at $102.18 on Friday. Neurocrine Biosciences, Inc. has a 52-week low of $71.85 and a 52-week high of $119.65. The stock has a market cap of $9.53 billion, a price-to-earnings ratio of 601.03, a PEG ratio of 1.12 and a beta of 1.21. The company has a quick ratio of 6.99, a current ratio of 7.08 and a debt-to-equity ratio of 0.83. The business has a 50-day moving average price of $109.34 and a 200-day moving average price of $100.68.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.63 by ($0.07). Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The firm had revenue of $222.09 million during the quarter, compared to analysts’ expectations of $211.31 million. During the same quarter in the previous year, the business earned $0.52 earnings per share. The company’s revenue for the quarter was up 46.3% compared to the same quarter last year. As a group, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 0.88 EPS for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Further Reading: Differences Between Momentum Investing and Long Term Investing

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.